Healthcare-associated infection in hematopoietic stem cell transplantation patients: risk factors and impact on outcome  by Mendes, Elisa Teixeira et al.
International Journal of Infectious Diseases 16 (2012) e424–e428Healthcare-associated infection in hematopoietic stem cell transplantation
patients: risk factors and impact on outcome
Elisa Teixeira Mendes a,*, Frederico Dulley b, Mariusa Basso a, Marjorie Vieira Batista a, Fabio Coracin b,
Thais Guimara˜es a, Maria Aparecida Shikanai-Yasuda a, Anna Sara Levin a, Silvia Figueiredo Costa a
aDepartamento de Molestias Infecciosas, Hospital das Clı´nicas, Faculdade de Medicina, Universidade de Sa˜o Paulo, Sa˜o Paulo, Brazil
b Servic¸o de Transplante de Medula O´ssea da Disciplina de Hematologia e Hemoterapia, Faculdade de Medicina, Universidade de Sa˜o Paulo, Sa˜o Paulo, Brazil
A R T I C L E I N F O
Article history:
Received 25 May 2011
Accepted 12 January 2012
Corresponding Editor: William Cameron,
Ottawa, Canada
Keywords:
Hematopoietic stem cell transplant
infection
Healthcare-associated infection
S U M M A R Y
Objective: The objective of this study was to analyze the incidence of and risk factors for healthcare-
associated infections (HAI) among hematopoietic stem cell transplantation (HSCT) patients, and the
impact of such infections on mortality during hospitalization.
Methods: We conducted a 9-year (2001–2009) retrospective cohort study including patients submitted
to HSCT at a reference center in Sa˜o Paulo, Brazil. The incidence of HAI was calculated using days of
neutropenia as the denominator. Data were analyzed using EpiInfo 3.5.1.
Results: Over the 9-year period there were 429 neutropenic HSCT patients, with a total of 6816 days of
neutropenia. Bloodstream infections (BSI) were the most frequent infection, presenting in 80 (18.6%)
patients, with an incidence of 11.7 per 1000 days of neutropenia. Most bacteremia was due to Gram-
negative bacteria: 43 (53.8%) cases were caused by Gram-negative species, while 33 (41.2%) were caused
by Gram-positive species, and four (5%) by fungal species. Independent risk factors associated with HAI
were prolonged neutropenia (odds ratio (OR) 1.07, 95% conﬁdence interval (CI) 1.04–1.10) and duration
of fever (OR 1.20, 95% CI 1.12–1.30). Risk factors associated with death in multivariate analyses were age
(OR 1.02, 95% CI 1.01–1.43), being submitted to an allogeneic transplant (OR 3.08, 95% CI 1.68–5.56), a
microbiologically documented infection (OR 2.96, 95% CI 1.87–4.6), invasive aspergillosis disease (OR
2.21, 95% CI 1.1–4.3), and acute leukemias (OR 2.24, 95% CI 1.3–3.6).
Conclusions: BSI was the most frequent HAI, and there was a predominance of Gram-negative
microorganisms. Independent risk factors associated with HAI were duration of neutropenia and fever,
and the risk factors for a poor outcome were older age, type of transplant (allogeneic), the presence of a
microbiologically documented infection, invasive aspergillosis, and acute leukemia. Further prospective
studies with larger numbers of patients may conﬁrm the role of these risk factors for a poor clinical
outcome and death in this transplant population.
 2012 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Infection remains a major cause of morbidity and mortality in
hematopoietic stem cell transplantation (HSCT) patients, although
better prevention and treatment of the infectious diseases have
improved the outcomes of transplantation in the past decade.1
The highest risk of infection occurs after the conditioning
regimen, until neutrophil engraftment. During this phase, the
patient usually experiences a severe and prolonged neutropenia,
has a central venous catheter and breaks in the mucocutaneous
barrier caused by mucositis, and may have acute graft-versus-host
disease (GVHD).1,2 Therefore, surveillance of nosocomial infections
during the neutropenic phase is essential for the treatment of* Corresponding author. Tel.: +55 11 30696530; fax: +55 11 30696444.
E-mail address: elisa-mendes@bol.com.br (E.T. Mendes).
1201-9712/$36.00 – see front matter  2012 Published by Elsevier Ltd on behalf of In
doi:10.1016/j.ijid.2012.01.015patients undergoing HSCT, and a useful tool to control and prevent
such infections.3–5
The risk of death in HSCT is multifactorial, involving intrinsic
and extrinsic factors related to underlying disease, clinical
condition, and infectious complications during hospitalization.6
The aim of this study was to analyze the incidence of and the
risk factors for healthcare-associated infections (HAI) among HSCT
patients, and the impact of such infections on mortality during
hospitalization.
2. Methods
2.1. Setting
The study was conducted in an eight-bed unit, with a two-bed
intensive care unit, at a 2200-bed university hospital, Hospital das
Clı´nicas, in Sa˜o Paulo, Brazil. By 2009, the hospital’s bone marrowternational Society for Infectious Diseases.
Table 1
Clinical characteristics, underlying diseases, types of procedures, interventions,
clinical evolution, and complications among neutropenic patients admitted to the
transplant unit of Hospital das Clı´nicas, Sa˜o Paulo, 2001–2009
Variable Frequency (%), or mean (range)
Total patients 429 (100)
Male 250 (58.3)
Female 179 (41.7)
Age (years) 30.8 (1–70)
Acute leukemia 132 (30.8)
Acute myeloid leukemia 67 (15.6)
Acute lymphoid leukemia 65 (15.2)
Aplastic anemia 76 (17.7)
Non-Hodgkin lymphoma 60 (14.0)
Hodgkin lymphoma 21 (4.9)
Chronic myeloid leukemia 38 (8.9)
Multiple myeloma 27 (6.3)
Transplant
Allogeneic 320 (74.6)
Autologous 109 (25.4)
GVHD 103 (24.0)
Mucositis 147 (34.3)
Long-term catheter 397 (92.5)
Duration of fever, days 4.6 (0–42)
Duration neutropenia, days 14.4 (1–94)
Length of stay, days 25.6 (1–144)
Fever of unknown origin 132 (30.8)
Healthcare-associated infection 277 (64.6)
Microbiologically documented infection 147 (34.3)
Blood stream infection 80 (18.6)
Invasive aspergillosis 47 (11.0)
Possible 30 (7.0)
Probable 11 (2.6)
Proven 6 (1.4)
Death 143 (33.3)
GVHD, graft-versus-host disease.
Table 2
Etiology of blood stream infection among patients with neutropenia (n = 80) at the
transplant unit of Hospital das Clı´nicas, Sa˜o Paulo, 2001–2009
Agent Frequency (%)
Gram-negative 43 (53.8)
Pseudomonas aeruginosa 18 (22.5)
Klebsiella pneumoniae 1 (1.3)
Burkholderia cepacia 4 (5)
Acinetobacter sp 12 (15)
Stenotrophomonas maltophilia 3 (3.8)
Escherichia coli 3 (3.8)
Aeromonas sp 2 (2.5)
Gram-positive 33 (41.2)
Coagulase-negative Staphylococcus 16 (20)
Staphylococcus aureus 2 (2.5)
Enterococcus faecium 15 (18.7)
Fungi 4 (5)
Non-albicans Candidaa 4 (5)
Total 80 (100)
a C. krusei (n = 2), C. parapsilosis (n = 1), C. tropicalis (n = 1).
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to 12 new transplants a month.
2.2. Study design
We conducted a 9-year retrospective study of patients
undergoing HSCT at the transplant unit of Hospital das Clı´nicas,
Universidade de Sa˜o Paulo, Brazil, between January 1, 2001 and
December 31, 2009.
All neutropenic (neutrophil count <0.5  109/l) HSCT recipients
admitted to the transplant unit with some sign or symptom of
infection, such as fever, chills, tachycardia, or hypotension, were
included. Patients were followed daily from the ﬁrst day of
neutropenia until discharge or death. HAI surveillance data at the
HSCT unit were collected by a nurse from the hospital infection
control committee.
Infections were deﬁned and categorized according to the US
Centers for Disease Control and Prevention (CDC) deﬁnitions. The
end-points were a diagnosis of HAI during the hospitalization and
death.
The following variables were evaluated: sex, age, underlying
disease, type of transplant (autologous or allogeneic), occurrence
of acute GVHD and mucositis, presence of a central venous
catheter (CVC), type of CVC, fever, and duration of fever,
neutropenia, and hospitalization. Infection episodes were cate-
gorized by type, either acquired at the hospital (HAI) or in the
community, according to the site (blood stream infection (BSI),
pneumonia, urinary tract, diarrhea, typhlitis, invasive aspergillo-
sis, and other infections), and if it was a microbiologically
documented infection or not. Fever of unknown origin (FUO) was
also recorded.
2.3. Statistical analysis
All statistical analyses were performed using EpiInfo 3.5.1.
Categorical variables were analyzed by Fisher’s exact test or the
Chi-square test, as appropriate. Continuous variables were
analyzed by Mann–Whitney and Wilcoxon tests. Chi-square for
trend was used to analyze rates of BSI and the main agents causing
BSI during the last 5 years of the study. A p-value of 0.05 was
considered signiﬁcant.
A bivariate model was initially adjusted with the diagnosis of
HAI during hospitalization as the response variable (‘yes’ or ‘no’)
and the covariates of interest to the study, one by one, as predictor
variables. Based on these simple models, a multivariable model
was adjusted, with the status of the individual as the response
variable and containing as predictor variables those with p-values
of effect estimates less than 0.25 in the simple adjustments, and
which, after multivariable adjustments, had a p-value below 0.05.
Using the same steps, another multivariate regression analysis was
performed, with the clinical evolution of the episode of neutrope-
nia as the response variable (death or survival). A Kaplan–Meier
curve was generated to compare survival among patients with and
without BSI.
3. Results
Four hundred and twenty-nine patients with 6816 days of
neutropenia (mean duration of neutropenia 14.4 days) were
included in the study. The main characteristics of the patients are
described in Table 1. Most patients (74.6%) underwent an
allogeneic HSCT, and the most common underlying disease was
aplastic anemia, with 76 (17.7%) patients, followed by acute
myeloid leukemia in 67 (15.6%) and acute lymphoid leukemia in 65
(15.2%). Mucositis was present in 147 (34.3%) and acute GVHD in
103 (24.0%) patients (Table 1).The mean length of hospitalization was 25.6 days. The
incidence density of HAI was 40.6 per 1000 days of neutropenia.
Among all cases of fever, 132 (30.8%) were attributed to FUO, and
147 (34.3%) patients presented at least one conﬁrmed microbio-
logical diagnosis during hospitalization. Among sites of infection,
BSI was most frequent, with 80 (18.6%) cases, followed by
pneumonia (11.7%) and diarrhea (6.3%). A urinary tract infection
accounted for 13 cases (3.0%) and ‘other infections’ totaled 24 cases
(5.6%).
Gram-negative bacteria were responsible for 43 (53.8%) of the
BSI, while 33 cases (41.2%) were due by Gram-positive bacteria and
four (5%) to fungi. The most frequently isolated bacteria were
Pseudomonas aeruginosa (22.5%), followed by coagulase-negative
Staphylococcus (CoNS; 20%) and Enterococcus faecium (18.7%)
(Table 2). The trend of BSI remained stable for Gram-negative
Table 3
Bivariate analysis and multivariate analysis of risk factors associated with healthcare-associated infection (HAI) among HSCT patients
Variable HAI (n = 277), n (%) Not HAI (n = 152), n (%) Bivariate analysis Multivariate analysis
OR (95% CI) p-Value OR (95% CI) p-Value
Sex
Male 164 (65.6) 86 (34.4) 1.33 (0.74–1.66) 0.67 - -
Female 113 (63.1) 66 (39.2) 1
Age, years, mean (range) 29.6 (1–69) 32.8 (2–70) - 0.057 1.01 (0.99–1.02) 0.17
Acute leukemia 93 (70.5) 39 (29.5) 1.46 (0.94–2.29) 0.11 0.95 (0.53–1.58) 0.86
Aplastic anemia 21 (13.8) 54 (19.5) 0.87 (0.45–2.65) 0.50 - -
Transplant
Allogeneic 224 (70) 96 (30) 2.45 (1.57–3.85) <0.00001 1.82 (0.84–2.76) 0.16
Autologous 53 (48.6) 56 (51.4) 1
Days of fever, mean (range) 6.2 (0–42) 1.6 (0–17) - <0.00001 1.20 (1.12–1.30) <0.0001
Days of neutropenia, mean (range) 17.29 (1–94) 9.14 (1–37) - <0.00001 1.07 (1.04–1.10) <0.0001
Mucositis 102 (75.6) 33 (24.4) 2.1 (1.33–3.31) 0.001 1.28 (0.67–2.43) 0.75
Acute GVHD 74 (74.3) 23 (23.7) 2.04 (1.22–3.4) 0.008 1.27 (0.61–2.62) 0.51
OR, odds ratio; CI, conﬁdence interval; GVHD, graft-versus-host disease.
Table 4
Bivariate and multivariate logistic regression analysis of variables associated with death among patients with neutropenia at the transplant unit of Hospital das Clı´nicas, Sa˜o
Paulo, 2001–2009
Variable Died (n = 143) Survived (n = 286) Bivariate analysis Multivariate analysis
OR (95% CI) p-Value OR (95% CI) p-Value
Sex
Male 88 162 1.22 (0.81–1.85) 0.38 - -
Female 55 124
Age, years, mean (range) 32.8 (3–70) 29.7 (1–70) - 0.095 1.02 (1.01–1.43) 0.0003
Acute leukemia 60 72 2.14 (1.4–3.2) 0.0003 2.24 (1.3–3.6) 0.001
Aplastic anemia 22 53 0.79 (0.45–1.36) 0.45 - -
Transplant
Allogeneic 123 197 2.77 (1.64–4.82) 0.0001 3.08 (1.68–5.56) 0.0003
Autologous 20 89
Days of fever, mean (range) 5.8 (0–42) 4 (0–41) - 0.001 1.01 (0.98–1.05) 0.26
Days of neutropenia, mean (range) 15.3 (1–63) 13.9 (1–94) - 0.24 - -
Length of stay, mean (range) 28 (1–99) 24.4 (1–144) - 0.016 - -
Microbiologically documented infection 71 76 2.71 (1.78–4.14) <0.0001 2.96 (1.87–4.6) <0.001
Blood stream infection 41 39 2.53 (1.55–4.18) 0.0002 1.08 (0.47–2.47) 0.8
Gram-negative 23 20 2.54 (1.33–4.85) 0.005 1.5 (0.57–3.9) 0.39
Gram-positive 14 18 1.61 (0.76–3.36) 0.2 - -
Healthcare-associated infection 109 168 2.24 (1.43–3.56) 0.0005 1.19 (0.69–2.05) 0.5
Invasive aspergillosis 26 21 2.8 (1.51–5.18) 0.001 2.21 (1.1–4.3) 0.02
OR, odds ratio; CI, conﬁdence interval.
Figure 1. Kaplan–Meier survival curve of intravascular catheter-related blood
stream infection associated with decreased survival of patients during
hospitalization (days of hospitalization).
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however BSI due to CoNS showed a signiﬁcant reduction (p = 0.05).
Forty-seven episodes of invasive aspergillosis were diagnosed;
30 of them were classiﬁed as ‘possible’ aspergillosis, 11 as
‘probable’, and six as ‘proven’ disease. The incidence of invasive
aspergillosis was 6.9 per 1000 days of neutropenia.
Risk factors associated with HAI on multivariate analysis were
duration of neutropenia (p < 0.0001) and duration of fever
(p < 0.0001). Allogeneic transplantation, GVHD, and mucositis
were risk factors for HAI only in the bivariate analysis (Table 3).
Table 4 shows the results of bivariate regression analysis of
predictors of death during hospitalization, and shows in the
multivariate analysis those variables that remained associated
with death in the ﬁnal model: age, acute leukemia, allogeneic
transplant, microbiologically documented infection, and invasive
aspergillosis. A survival analysis with the Kaplan–Meier method
revealed that the presence of BSI signiﬁcantly increased the risk of
death among HSCT patients during their hospital stay (Figure 1).
4. Discussion
Infectious diseases are a frequent cause of complications in
HSCT patients, resulting in a more prolonged hospitalization and
E.T. Mendes et al. / International Journal of Infectious Diseases 16 (2012) e424–e428 e427increased morbidity, mortality, and costs.1 The risk of infection is
more critical within the ﬁrst 3 weeks after transplantation, during
the neutropenic phase, so efforts towards preventing infections
during this period are closely linked with hospital infection
control.6
Few studies have assessed the risk of HAI among HSCT patients
during the neutropenia phase.7,8 Hence we considered it important
to perform surveillance of infection among patients at risk, using
days of neutropenia as the denominator. The present study showed
a high rate of HAI – 40.6 per 1000 days of neutropenia – among
HSCT patients during neutropenia, comparable to previously
reported HAI rates, varying from 35.5 to 38.9 per 1000 days of
neutropenia.8,9
Over the past 10 years, the molecular diagnosis of bacterial and
fungal infections in febrile neutropenic patients has been proposed
in order to increase sensitivity and make the earliest possible clinical
diagnosis, reducing the severity of the infection and limiting
prophylactic therapies.10,11 However, despite efforts to increase
the microbiological diagnosis in these patients, FUO remains an
important cause of antibiotic use among HSCT patients; FUO has
only recently been included in hospital surveillance of neutropenic
patients,12 and data on the rate of FUO using days of neutropenia as
the denominator are still scarce. In a study conducted by Engelhart
et al.,7 the incidence density of FUO was 18.5 per 1000 days of
neutropenia. We identiﬁed 132 patients with FUO (30.8%), with an
incidence density of 19.4 cases per 1000 days of neutropenia.
Bloodstream infection was the most frequent HAI; among the
147 microbiologically documented infections, 68 (46.3%) were BSI,
and there was a predominance of Gram-negative microorganisms.
These results could reﬂect the high rate of infection due to Gram-
negative organisms in our hospital and could be useful to address
measures to prevent and control such infections. It is known that in
the 1970s approximately 70% of BSI in neutropenic patients were
caused by Gram-negative bacteria, with a fatality rate close to
40%.13 In the 1980s there was a change in this proﬁle, and Gram-
positive bacteria became predominant, probably due to the
practice of antibiotic prophylaxis in febrile neutropenic patients
and an increase in the use of CVCs and myeloablative drugs.14
Currently a new tendency of Gram-negative prevalence has been
observed,15,16 as was the case in our series (53.8% Gram-negative).
A European review17 found an increased incidence of P. aeruginosa
in neutropenic patients with cancer in recent years (from 5% to
12%). In the present study P. aeruginosa was the main agent in BSI
cases (22.5%), followed by CoNS and E. faecium. We also showed a
trend towards a decrease in the incidence of CoNS BSI over the last
5 years of the study period, which corroborates the change in
etiology of BSI among neutropenic patients. In contrast, a
multicenter study in Brazil18 found CoNS as the main agent
associated with BSI (42.3%), followed by Staphylococcus aureus and
P. aeruginosa (both 11%). The increased rate of Gram-negative
bacterial resistance seen in our hospital in recent years19 most
likely accounts for this shift. This fact can be explained in part by
two clusters of infection due to carbapenem-resistant P. aeruginosa
that occurred in our bone marrow unit (in 2007 and 2009). These
clusters were controlled by simple measures, such as reinforce-
ment of hand hygiene and CVC care, especially in the shower.19
In the present study, the risk of HAI was higher in patients who
underwent an allogeneic compared to those who underwent an
autologous transplantation, a ﬁnding also observed by other
authors, particularly associated with BSI and pneumonia.3,12 It is
known that allogeneic HSCT usually results in a longer and more
severe neutropenia, as well as more prolonged hospitalization,
representing an important risk factor for nosocomial infection in this
population.12
The duration of fever was found to be an independent risk factor
associated with HAI. Since FUO was present in 30.8% of patientsand CVC-BSI was the most frequent HAI, the duration of fever
among patients who developed HAI could be related to the severity
of infection. Central line-associated BSI (CA-BSI) are associated
with a high risk of morbidity and mortality in HSCT patients, and
they were the most frequent infection found in our study.20 In the
present study, CA-BSI represented the most frequent site of
infection (18.6%), with an incidence of 11.7 per 1000 days of
neutropenia. However, this rate of BSI is slightly lower than those
reported previously of 13.5 and 12.9 episodes per 1000 days of
neutropenia.8,21 This result highlights the importance of CA-BSI for
the outcome in HSCT patients and reinforces the need for infection
control efforts to be focused on measures to prevent this infection.
A recent study found an increased risk of Gram-negative CVC-BSI
related to self-administered intravenous infusions, bathing habits,
and a lower frequency of needleless device changes.22 In another
study, Chaberny et al. reduced the CA-BSI rates among hematologic
patients by 35.8% with the implementation of transparent
dressings, chlorhexidine–silver sulfadiazine impregnated cathe-
ters, and educational campaigns aimed at encouraging hand
washing and disinfection before donning or after removing
gloves.23
Acute leukemia (both lymphoid and myeloid) was also an
independent risk factor for death. A multicenter study published in
201024 evaluated the outcome of acute myeloid leukemia (AML)
patients undergoing HSCT, and obtained a survival rate of 50% in 5
years (36–61%), while 15% of deaths were attributed to infectious
causes. Acute leukemias are reported as the main underlying
diseases among patients undergoing allogeneic transplantation,
and AML is the most prevalent among them.23 In contrast, among
autologous transplantation patients, multiple myeloma and
various types of lymphoma are the most frequent underlying
diseases,12 as was also demonstrated in this study (27% and 37%,
respectively). In the multivariate analysis, advanced age was also
found to have contributed to death. Among patients older than 60
years, the observed mortality was 50%, whereas among patients
younger than 30 years, death occurred in 30.7% of cases.
The fact that patients with a microbiologically documented
infection presented a higher risk for death may be related to the
low sensitivity of bacterial and fungal cultures. When the organism
is identiﬁed, we are probably facing a more severe infection with
large inoculums of the microorganism and delays or errors in
empirical therapy.18 This result could also be explained by the fact
that BSI was the most frequent HAI, and was responsible for 46.3%
of microbiologically documented infections.
Invasive fungal infections (IFI) remain an important cause of
morbidity and mortality among patients undergoing HSCT, with
incidence ranging from 10% to 15%.25 Since the 1980s, mainly due
to antifungal prophylaxis, candidemia has been replaced by
ﬁlamentous fungal infections, particularly Aspergillus spp.26 Our
hospital recommends the routine use of prophylaxis with
ﬂuconazole until 100 days after HSCT. During the study period,
only four cases of candidemia were identiﬁed, all caused by non-
albicans Candida, and invasive aspergillosis infections signiﬁcantly
increased the risk of mortality (rate of 55.3%). Similar results were
found by Cordonnier et al.,27 with a mortality rate of 66% due to
mould infections. This study suggests that even after control of
infection or cure, invasive aspergillosis indicates a poor prognosis,
with an increased mortality risk.
The main limitations of this study are related to the utilization
of retrospective data collected in routine surveillance. Therefore
some information is lacking that may have contributed to a better
assessment of the cases, such as bacterial susceptibility proﬁles,
clinical details about the development of cases, viral reactivation,
and the causes contributing to death.
In conclusion, BSI was the most frequent HAI, and there was a
predominance of Gram-negative microorganisms. Independent
E.T. Mendes et al. / International Journal of Infectious Diseases 16 (2012) e424–e428e428risk factors associated with HAI were duration of neutropenia and
fever, and the risk factors for a poor outcome were older age,
allogeneic type of transplant, the presence of a microbiologically
documented infection, invasive aspergillosis, and acute leukemia.
Further prospective studies with larger numbers of patients may
conﬁrm the role of these risk factors for a poor clinical outcome and
death in this transplant population.
Furthermore, in this study it is clear that the highest risk of HAI
was among patients undergoing allogeneic transplantation, with
the risk increasing signiﬁcantly with prolonged hospitalization and
neutropenia. Therefore the control and surveillance of infection in
these patients should be intensiﬁed on the wards and in day
hospitals in an attempt to avoid preventable disorders, improve
the quality of care, and prolong the survival of this population.
Conﬂict of interest: No conﬂict of interest to declare for all
authors.
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